» Articles » PMID: 30536183

Contribution of the OC Sensor Immunoassay in Comparison to the Hemoccult II Guaiac-test in Organized Colorectal Cancer Screening

Overview
Journal Eur J Epidemiol
Specialty Public Health
Date 2018 Dec 12
PMID 30536183
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Colorectal cancer (CRC) is a major cause of cancer-related death of worldwide with high incidence and mortality rate, accessible to a screening program in France, first with guaiac- based fecal occult blood test (g-FOBT) then with fecal immunochemical tests (FIT), since 2015, because of better accuracy. The aim of our study was to compare the characteristics of screen-detected lesions in two successive CRC screening campaigns, using two different tests (Hemoccult II and OC Sensor) in the department of Maine-et-Loire, and to precise the performance of these tests [participation rate, detection rates (DR), positive predictive value (PPV)]. Participants, invited by CAP SANTE 49, with polyps or cancer at the colonoscopy after a positive screening test between 01/01/2013 and 31/12/2016 were included. A guaiac-based fecal occult blood test (g-FOBT) was used from January 2013 to December 2014 and a FIT was used from June 2015 to December 2016). 2575 participants, 642 in g-FOBT group and 1933 in FIT group had lesions. Participation rate was not different between tests (p = 0.104), whereas DR and PPV were statistically higher in FIT for all lesions (2.61, 95% CI [2.50-2.70] vs 0.93, 95% CI [0.90-1.00], p < 0.0001 and 64.84, 95% CI [63.10-66.60], 50.00, 95% CI [47.30-52.70], p < 0.0001 respectively). FIT detects more precancerous lesions (adenomas, p < 0.001, and advanced adenomas, p < 0.001) than g-FOBT but g-FOBT detects more serrated polyps (p = 0.025). AAs were more in right colon in FIT than g-FOBT (p = 0.035). No different participation rate was detected between FIT and g-FOBT but DR and PPV of all lesions was higher with FIT.

Citing Articles

Innovative laboratory techniques shaping cancer diagnosis and treatment in developing countries.

Lawal A, Ogunniyi T, Oludele O, Olorunfemi O, Okesanya O, Ogaya J Discov Oncol. 2025; 16(1):137.

PMID: 39921787 PMC: 11807038. DOI: 10.1007/s12672-025-01877-w.


Supply and quality of colonoscopy according to the characteristics of gastroenterologists in the French population-based colorectal-cancer screening program.

Koivogui A, Vincelet C, Abihsera G, Ait-Hadad H, Delattre H, Le Trung T World J Gastroenterol. 2023; 29(9):1492-1508.

PMID: 36998423 PMC: 10044857. DOI: 10.3748/wjg.v29.i9.1492.


Colorectal Cancer Screening With High Risk-Factor Questionnaire and Fecal Immunochemical Tests Among 5, 947, 986 Asymptomatic Population: A Population-Based Study.

Zhang M, Zhao L, Zhang Y, Jing H, Wei L, Li Z Front Oncol. 2022; 12:893183.

PMID: 35712520 PMC: 9195590. DOI: 10.3389/fonc.2022.893183.


Detection of Colorectal Cancer and Advanced Adenoma by Liquid Biopsy (Decalib Study): The ddPCR Challenge.

Junca A, Tachon G, Evrard C, Villalva C, Frouin E, Karayan-Tapon L Cancers (Basel). 2020; 12(6).

PMID: 32517177 PMC: 7352444. DOI: 10.3390/cancers12061482.


Objectives, design and main findings until 2020 from the Rotterdam Study.

Ikram M, Brusselle G, Ghanbari M, Goedegebure A, Ikram M, Kavousi M Eur J Epidemiol. 2020; 35(5):483-517.

PMID: 32367290 PMC: 7250962. DOI: 10.1007/s10654-020-00640-5.

References
1.
Jouve J, Remontet L, Dancourt V, Lejeune C, Benhamiche A, Faivre J . Estimation of screening test (Hemoccult) sensitivity in colorectal cancer mass screening. Br J Cancer. 2001; 84(11):1477-81. PMC: 2363664. DOI: 10.1054/bjoc.2001.1752. View

2.
Ko C, Dominitz J, Nguyen T . Fecal occult blood testing in a general medical clinic: comparison between guaiac-based and immunochemical-based tests. Am J Med. 2003; 115(2):111-4. DOI: 10.1016/s0002-9343(03)00294-8. View

3.
Faivre J, Dancourt V, Lejeune C, Tazi M, Lamour J, Gerard D . Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology. 2004; 126(7):1674-80. DOI: 10.1053/j.gastro.2004.02.018. View

4.
Federici A, Rossi P, Borgia P, Bartolozzi F, Farchi S, Gausticchi G . The immunochemical faecal occult blood test leads to higher compliance than the guaiac for colorectal cancer screening programmes: a cluster randomized controlled trial. J Med Screen. 2005; 12(2):83-8. DOI: 10.1258/0969141053908357. View

5.
Winawer S, Zauber A, Fletcher R, Stillman J, OBrien M, Levin B . Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology. 2006; 130(6):1872-85. DOI: 10.1053/j.gastro.2006.03.012. View